DE4498692T1 - Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung - Google Patents

Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung

Info

Publication number
DE4498692T1
DE4498692T1 DE4498692T DE4498692T DE4498692T1 DE 4498692 T1 DE4498692 T1 DE 4498692T1 DE 4498692 T DE4498692 T DE 4498692T DE 4498692 T DE4498692 T DE 4498692T DE 4498692 T1 DE4498692 T1 DE 4498692T1
Authority
DE
Germany
Prior art keywords
preventing
making
methods
pharmaceutical compositions
curing cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4498692T
Other languages
English (en)
Inventor
Gyula Kulcsar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNAL KFT
Original Assignee
IMMUNAL KFT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNAL KFT filed Critical IMMUNAL KFT
Publication of DE4498692T1 publication Critical patent/DE4498692T1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE4498692T 1993-11-09 1994-11-08 Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung Withdrawn DE4498692T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9303171A HU213677B (en) 1993-11-09 1993-11-09 Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
PCT/HU1994/000049 WO1995013061A1 (en) 1993-11-09 1994-11-08 Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation

Publications (1)

Publication Number Publication Date
DE4498692T1 true DE4498692T1 (de) 1996-02-22

Family

ID=10984131

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4498692T Withdrawn DE4498692T1 (de) 1993-11-09 1994-11-08 Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung
DE69429806T Expired - Lifetime DE69429806T2 (de) 1993-11-09 1994-11-08 Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69429806T Expired - Lifetime DE69429806T2 (de) 1993-11-09 1994-11-08 Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung

Country Status (18)

Country Link
EP (1) EP0679081B1 (de)
JP (1) JPH08508045A (de)
KR (1) KR100363779B1 (de)
CN (1) CN1128615C (de)
AT (1) AT408414B (de)
AU (1) AU682735B2 (de)
CA (1) CA2151826C (de)
CH (1) CH686867A5 (de)
CZ (1) CZ286633B6 (de)
DE (2) DE4498692T1 (de)
ES (1) ES2094702B1 (de)
FI (1) FI953369A (de)
HU (1) HU213677B (de)
NL (1) NL195007C (de)
PL (1) PL177981B1 (de)
RU (1) RU2138257C1 (de)
SE (1) SE521049C2 (de)
WO (1) WO1995013061A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864024A (en) * 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
AU6340198A (en) * 1997-03-04 1998-09-22 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resultingin chronic conditions
RU2108786C1 (ru) * 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2164013B1 (es) * 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
WO2003030890A1 (fr) * 2001-10-05 2003-04-17 Tetsuro Asao Activateurs du systeme immunitaire
WO2003061568A2 (en) * 2002-01-16 2003-07-31 Eliezer Rapaport Methods and therapeutic compositions in the treatment of advanced cancer
CA2589995C (en) * 2004-12-17 2016-01-05 Alan B. Cash Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for treating cancer
WO2007026996A1 (en) * 2005-08-03 2007-03-08 National Cancer Center Glucosamine and derivatives thereof useful as tg inhibitors
KR100878585B1 (ko) 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备***药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备***药物中的应用
WO2015137383A1 (ja) * 2014-03-11 2015-09-17 味の素株式会社 癌化学療法の補助剤
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE2021969A1 (de) * 1970-04-29 1971-11-18 Boettger Kg Pharmazeutische Un Verfahren zur Herstellung eiweissfreier Praeparate
FR2201879B2 (de) * 1972-05-19 1976-01-23 Tixier Georges Fr
FR2244468A1 (en) * 1973-07-31 1975-04-18 Passwater Richard Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4880918A (en) * 1982-07-13 1989-11-14 Eliezer Rapaport Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
EP0220537B1 (de) * 1985-10-23 1990-07-25 Dr. Kurt Mulli Nachf. GmbH & Co. KG Thymusextraktfraktionen enthaltende pharmazeutische Zusammensetzung
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability

Also Published As

Publication number Publication date
EP0679081B1 (de) 2002-02-06
CZ177395A3 (en) 1996-01-17
FI953369A0 (fi) 1995-07-07
CZ286633B6 (cs) 2000-05-17
PL309600A1 (en) 1995-10-30
AT408414B (de) 2001-11-26
DE69429806D1 (de) 2002-03-21
CN1116406A (zh) 1996-02-07
KR100363779B1 (ko) 2003-03-06
RU2138257C1 (ru) 1999-09-27
ES2094702A1 (es) 1997-01-16
CA2151826C (en) 2008-06-17
FI953369A (fi) 1995-07-07
DE69429806T2 (de) 2002-09-12
EP0679081A1 (de) 1995-11-02
NL195007C (nl) 2003-06-10
AU682735B2 (en) 1997-10-16
CH686867A5 (de) 1996-07-31
SE521049C2 (sv) 2003-09-23
NL9420013A (nl) 1995-10-02
WO1995013061A1 (en) 1995-05-18
ATA900894A (de) 2001-04-15
ES2094702B1 (es) 1998-02-16
JPH08508045A (ja) 1996-08-27
CN1128615C (zh) 2003-11-26
AU1074995A (en) 1995-05-29
SE9502474L (sv) 1995-07-06
HU9303171D0 (en) 1994-01-28
SE9502474D0 (sv) 1995-07-06
CA2151826A1 (en) 1995-05-18
PL177981B1 (pl) 2000-02-29
HU213677B (en) 1997-12-29

Similar Documents

Publication Publication Date Title
ATA125988A (de) Pharmazeutische cefuroximaxetil-zusammensetzung und verfahren zu ihrer herstellung
DE69331176D1 (de) Knochenzement und Verfahren zu seiner Herstellung
DE69411604D1 (de) Wirkstoffzusammensetzung und Verfahren zu ihrer Herstellung
DE59401343D1 (de) Medizinisches pflastermaterial sowie verfahren zu seiner herstellung
DE69434944D1 (de) Organisch- anorganische Verbundpartikel und Verfahren zu ihrer Herstellung
DE4498692T1 (de) Pharmazeutische Kompositionen zum Vorbeugen und Heilen von Krebserkrankungen und Verfahren zu ihrer Herstellung
ATA902992A (de) Antigeschwulstmittel und verfahren zu ihrer herstellung
ATE234291T1 (de) Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
CY2008012I1 (el) Υδροξυεστερες ραπαμυκινης, διαδικασια για τη παρασκευη τους και φαρμακευτικες συνθεσεις περιεχουσες αυτες
DE69402899D1 (de) Entladungsgefäss und Verfahren zu dessen Herstellung
DE69314950D1 (de) Okulaerdarreichungsform und verfahren zu ihrer herstellung
DE59408355D1 (de) Cycloolefincopolymere und Verfahren zu ihrer Herstellung
DE69407907D1 (de) Zementprodukte und Verfahren zu deren Herstellung
DE69302810D1 (de) Verbundwerkstoffe und verfahren zu ihrer herstellung
DE69216772D1 (de) Medizinische Behälter und Verfahren zu ihrer Herstellung
ATA195788A (de) Tripeptide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69423082D1 (de) Supraleiter und Verfahren zu dessen Herstellung
DE59305621D1 (de) Etikett und Verfahren zu dessen Herstellung
DE69433296D1 (de) Eisen-lactoferrin kombination und verfahren zu ihrer herstellung
DE69224861D1 (de) Neue Phenylacetamidderivate und Verfahren zu ihrer Herstellung
ATE143010T1 (de) Pyridazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69608490D1 (de) Maltitol Zusammensetzung und Verfahren zu ihrer Herstellung
ATA56790A (de) Thieno-triazolo-diazepinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
ATA95690A (de) Thieno-triazolo-diazepinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE69329060D1 (de) Verfahren zur herstellung von hochdosiertem glutathion und dabei hergestellte tabletten und kapseln

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee